Cori-Fill fluid dosage assembly is fast and accurate
Mass flow metering and control specialist Bronkhorst, based in Cambridgeshire, UK, is offering an alternative to the gravimetric or weighing scale method of dosing additives, which promises shorter processing times, better product results and improved working atmospheres.
The company's Cori-Fill compact fluid dosage assembly, which combines a Cori-Flow or mini Cori-Flow flowmeter with a suitable valve or pump, is capable of dosing the exact amount of fluid, while multiple instruments can be used for the simultaneous dosing of compounds.
The instrument is suitable for batching, blending, dosing, filling and sterilisation applications at flow rates between 0.4g/hr and 600kg/hr. Aimed at the pharmaceutical, chemical and life sciences industries, among others, it takes up little room and requires no complex programming of additional hardware.
Unlike the conventional gravimetric method of dosing, which uses a shut-off valve and a weighing scale located under the valve's outlet nozzle, the Cori-Fill technology, with integrated batch counters and the facility to operate shut-off valves, is capable of dosing the precise amount of compound into the collecting vessel, with just a brief reset command to start the next batch.
The company says the Coriolis direct mass measurement method eliminates volumetric variation caused by changing temperatures, viscosities and densities of the ingredients, leading to accurate, repeatable quantities batch after batch.
Cori-Fill assemblies are offered with a choice of Cori-Flow instruments, for flow rates between 20g/hr to 600kg/hr, or the highly compact mini Cori-Flow series, for capacities from 0.4g/hr up to 30kg/hr. Either instrument type can be combined with a shut-off valve, for short batch sequences down to <0.3sec, a proportional valve, for longer dosing times >5 seconds, or a gear pump, for dosing without the need for pressurised vessels.
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
Read moreAt Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Trending Articles
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology